2026³â 02¿ù 28ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Crown Bioscience Appoints John Gu as Chief Executive Officer

´º½ºÀÏÀÚ: 2025-03-29

SAN DIEGO -- Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has appointed John Gu as its new Chief Executive Officer (CEO). Following his tenure as interim CEO and his role as Chief Operating Officer (COO), John Gu is recognized as an esteemed leader with broad business acumen and extensive experience in digital strategy, business transformation, and genomic data analysis. His unparalleled experience is particularly relevant in streamlining AI-driven approaches to advance drug discovery and development processes, marking him as a remarkable asset in steering Crown Bioscience to the forefront of biotechnological innovation.

“Gu’s global perspective and commitment to collaboration and excellence have laid a strong foundation for visionary leadership,” said Tim Lowery, President of JSR Life Sciences, Crown Bioscience’s parent company. “His pivotal role will undoubtedly advance our mission to positively impact global patient health while steering the company towards greater success.”

Gu joined Crown Bioscience in 2020 as Chief Operating Officer after holding leadership roles at companies including Genuity Science (formerly WuXi Nextcode), Silver Sand Technologies, and Baidu. His impactful strategies in the advancement of global technology platforms and operations and client services have equipped him well for this leadership position.

“I am motivated by the shared vision and capabilities that form the backbone at Crown Bioscience,” said Gu. “Our collective efforts aim to set new benchmarks in oncology drug discovery, and enhance patient outcomes globally.”

As CEO (and continuing as COO), Gu will focus on growth by expanding the company’s offerings and global presence, enhancing operational efficiency, and strengthening partnerships to foster innovation. Under Gu’s leadership, Crown Bioscience is poised to significantly enhance its contributions to global human health, reinforcing its reputation for delivering an industry-leading portfolio of services and platforms that address the complex needs of its clients.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Ypê Deepens Partnership with Rimini Street to Accelerate Agentic AI and Maximize ERP Value
SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe
Genon Establishes Indonesian Subsidiary to Accelerate AI Transformation Across Asia
NetApp Data Platform Powers Data Operations for Super Bowl LX
Concept Medical Begins STARS DAPT Trial With First Patient for Abluminus NP Polymer-Free DES
Research From Lenovo Reveals AI Is Paying Off, Yet Most CIOs Aren¡¯t Ready for What Comes Next
Revolutionizing 5G Network Slice Testing: Industry-First Performance Methodology by Ookla and Ericsson

 

Parse Biosciences Launches Workflow for Immune Repertoire and Transcri...
Copeland Advances AI and Digital Strategy with Acquisition of Bueno An...
Vestas Secures 390 MW Offshore Order in South Korea
Syngenta to Tackle Global Farm Challenges at WEF, Driving AI Innovatio...
Philip Morris International Opens Dialogue on the Future of Human Cogn...
Crown Bioscience San Diego Lab Earns CAP Accreditation, Expands Clinic...
Axelspace Signs MoU with Ethiopian Company to Address Social Challenge...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬银öõ(ÜÄÒ¬ÜØ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..